Hoya’s Reports Strong IOL Sales in Fiscal 2017 Fourth Quarter

May 12, 2017: By Jon Swedien

Hoya logoHoya’s intraocular lens (IOL) sales were strong during its fiscal 2017 fourth quarter—Jan. 1 to March 31, 2017, according to the Japanese company.

The firm announced May 11 that its IOL sales for cataracts continued to perform well in Japan, after being introduced in the previous fiscal year. Outside of Japan, IOL sales grew, outpacing performance for the same period in the prior fiscal year “by a significant margin,” Hoya said.

Hoya’s Life Care business segment, which includes eyeglass lenses, contact lenses, and intraocular lenses (IOLs), plus other products, saw an increase in revenues of 3.5 percent, with sales totaling 83,752 million yen (US $739 million, as of May 12, 2017) in the quarter.

Hoya reported that its overall revenues increased 3.8 percent to 126,304 million yen (US $1.12 billion) in the company’s 2017 fiscal fourth quarter.

Revenues for the fiscal year ended March 31, 2017, totaled 478,927 million yen (US $4.23 billion), down 5.3 percent year over year.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022